Literature DB >> 17616542

Short term outcomes of the first round of a pilot colorectal cancer screening programme with guaiac based faecal occult blood test.

Bernard Denis1, Marcel Ruetsch, Patrick Strentz, Jean Yves Vogel, Francis Guth, Jean Marc Boyaval, Xavier Pagnon, Jean François Ebelin, Isabelle Gendre, Philippe Perrin.   

Abstract

OBJECTIVE: To assess both feasibility and short term outcomes of a population based colorectal cancer screening programme using a biennial guaiac based faecal occult blood test (gFOBT).
METHOD: All participants were invited by mail to take part in a screening programme using a non-rehydrated gFOBT. The gFOBTs were first provided by general practitioners (GPs) and then directly mailed to individuals who failed to comply after two invitations. The setting was a French administrative district: Haut-Rhin (710,000 inhabitants). 182,981 residents aged 50-74 years were invited to participate.
RESULTS: 19,274 people (10.5%) were excluded from gFOBT screening and 90,706 completed a gFOBT, so that the participation rate was 55.4% of those eligible. 76.5% of the completed gFOBTs were provided by GPs and 15.5% by direct mailing. The gFOBT positivity rate was 3.4%. The positive predictive value was 42.7% for neoplasia (women 30.8%, men 52.5%), 23.6% for advanced adenoma, and 7.6% for cancer. The number of normal colonoscopic procedures (without neoplasia) needed to be performed for each colonoscopy detecting an advanced neoplasia was 1.8, lower in men (1.2) than in women (3.4), and decreasing with age. Detection rates for neoplasia and cancer were 12.8 and 2.3 per 1000 people screened. 206 adenocarcinomas were detected: 47.6% were stage I and 23.8% stage II. The direct cost was estimated at euro 29.3 per screened person and euro 13,466 per cancer detected.
CONCLUSIONS: Participation and diagnostic yield of controlled trials of gFOBT screening are reproducible in the real world at an acceptable cost through an organised population based programme involving GPs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616542      PMCID: PMC2095636          DOI: 10.1136/gut.2007.126037

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  29 in total

1.  Cost-effectiveness of screening for colorectal cancer: evidence from the Nottingham faecal occult blood trial.

Authors:  David K Whynes
Journal:  J Med Screen       Date:  2004       Impact factor: 2.136

2.  [Mass screening for colorectal cancer in France. Experience in 165,000 people in the department of Calvados].

Authors:  G Launoy; C Herbert; J P Vallée; N Desoubeaux; J M Réaud; V Ollivier; V Bouvier; A Flachs; D Arsène; A Valla; M Gignoux
Journal:  Gastroenterol Clin Biol       Date:  1996

Review 3.  Complications of colonoscopy and flexible sigmoidoscopy.

Authors:  J D Waye; O Kahn; M E Auerbach
Journal:  Gastrointest Endosc Clin N Am       Date:  1996-04

4.  Randomised controlled trial of faecal-occult-blood screening for colorectal cancer.

Authors:  J D Hardcastle; J O Chamberlain; M H Robinson; S M Moss; S S Amar; T W Balfour; P D James; C M Mangham
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

5.  Randomised study of screening for colorectal cancer with faecal-occult-blood test.

Authors:  O Kronborg; C Fenger; J Olsen; O D Jørgensen; O Søndergaard
Journal:  Lancet       Date:  1996-11-30       Impact factor: 79.321

Review 6.  Adverse effects of screening mammography.

Authors:  Stephen A Feig
Journal:  Radiol Clin North Am       Date:  2004-09       Impact factor: 2.303

7.  Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study.

Authors:  J S Mandel; J H Bond; T R Church; D C Snover; G M Bradley; L M Schuman; F Ederer
Journal:  N Engl J Med       Date:  1993-05-13       Impact factor: 91.245

8.  Results of the first round of a demonstration pilot of screening for colorectal cancer in the United Kingdom.

Authors: 
Journal:  BMJ       Date:  2004-07-05

9.  Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging.

Authors:  Jessica B O'Connell; Melinda A Maggard; Clifford Y Ko
Journal:  J Natl Cancer Inst       Date:  2004-10-06       Impact factor: 13.506

10.  The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years.

Authors:  G Gondal; T Grotmol; B Hofstad; M Bretthauer; T J Eide; G Hoff
Journal:  Scand J Gastroenterol       Date:  2003-06       Impact factor: 2.423

View more
  13 in total

1.  The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2013-08-22

2.  The dynamics of colorectal cancer management in 17 countries.

Authors:  Panos Kanavos; Willemien Schurer
Journal:  Eur J Health Econ       Date:  2010-01

3.  Incremental net benefit and acceptability of alternative health policies: a case study of mass screening for colorectal cancer.

Authors:  Pauline Chauvin; Jean-Michel Josselin; Denis Heresbach
Journal:  Eur J Health Econ       Date:  2011-02-09

4.  Colorectal cancer screening in Canada: results from the first round of screening for five provincial programs.

Authors:  D Major; H Bryant; M Delaney; S Fekete; L Gentile; M Harrison; V Mai; E Nicholson; Y Taylor
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

5.  Is the 'driving test' a robust quality indicator of colonoscopy performance?

Authors:  Nicholas M Kelly; John Moorehead; Tony Tham
Journal:  World J Gastrointest Endosc       Date:  2010-04-16

6.  A comparative study of faecal occult blood kits in a colorectal cancer screening program in a cohort of healthy construction workers.

Authors:  M Shuhaibar; C Walsh; F Lindsay; N Lee; P Walsh; P O'Gorman; G Boran; R McLoughlin; A Qasim; N Breslin; B Ryan; H O'Connor; C O'Morain
Journal:  Ir J Med Sci       Date:  2010-10-17       Impact factor: 1.568

7.  Socioeconomic position and participation in colorectal cancer screening.

Authors:  B L Frederiksen; T Jørgensen; K Brasso; I Holten; M Osler
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

Review 8.  Colorectal cancer screening: 20 years of development and recent progress.

Authors:  Miroslav Zavoral; Stepan Suchanek; Ondrej Majek; Premysl Fric; Petra Minarikova; Marek Minarik; Bohumil Seifert; Ladislav Dusek
Journal:  World J Gastroenterol       Date:  2014-04-14       Impact factor: 5.742

9.  Primary care endorsement letter and a patient leaflet to improve participation in colorectal cancer screening: results of a factorial randomised trial.

Authors:  P Hewitson; A M Ward; C Heneghan; S P Halloran; D Mant
Journal:  Br J Cancer       Date:  2011-08-09       Impact factor: 7.640

10.  Empirical evidence of the continuing improvement in cost efficiency of an endoscopic surveillance programme for gastric cancer in Singapore from 2004 to 2010.

Authors:  Hui Jun Zhou; Shu Chuen Li; Nasheen Naidoo; Feng Zhu; Khay Guan Yeoh
Journal:  BMC Health Serv Res       Date:  2013-04-15       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.